- Awakn Life Sciences (AWKN) has signed a licensing agreement with a partner in Portugal to support the launch of a chain of medical-psychedelic clinics
- Awakn will license the use of its clinical protocols for the treatment of AUD, Anxiety, Depression, Eating Disorders and PTSD for a period of 10 years
- Awakn is a Canadian biotechnology company researching, developing, and delivering psychedelic medicine to treat addiction
- Awakn Life Sciences Corp. (AWKN) opened trading at C$0.44
Awakn Life Sciences (AWKN) has signed a licensing agreement with a partner in Portugal.
The agreement will support the partner’s strategy to launch a new chain of medical-psychedelic clinics in Portugal.
Awakn will provide the Portuguese Partner with an exclusive licence for use of its clinical protocols for the treatment of AUD, Anxiety, Depression, Eating Disorders and PTSD in Portugal for a period of 10 years. Awakn will provide training and ongoing strategic, operational, risk management, and marketing support.
Awakn CEO Anthony Tennyson commented on the partnership.
“We are very pleased to expand our Licencing Partnership business by geography, into Portugal, and by scope into anxiety, depression, eating disorders, and PTSD. We are also delighted to work with our new partners in Portugal, who are deeply experienced in and knowledgeable of the Portuguese mental health treatment and wellness sectors. With Awakn being the first chain of psychedelic clinics in Europe, we have a wealth of knowledge to help accelerate the development and execution of their strategy. Importantly, this partnership will allow many people in Portugal to access new, more effective treatment options which are not currently available.”
About Awakn Life Sciences Corp.
Awakn is a Canadian biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction.
Awakn Life Sciences Corp. (AWKN) opened trading at C$0.44.
